Last updated: February 20, 2026
What is the case about?
Endo Pharmaceuticals Inc. filed patent infringement litigation against Impax Laboratories, Inc. in the U.S. District Court for the Central District of California (Case No. 1:12-cv-08317). The dispute involves patent rights related to a controlled-release formulation of oxymorphone, specifically patent US Patent Nos. 7,671,041 and 7,858,121. Endo alleges Impax's generic versions infringe these patents.
When did the litigation occur?
The initial complaint was filed on December 19, 2012. The case has a protracted procedural history, featuring motions to dismiss, claim construction hearings, and patent validity challenges, extending over several years. The final resolved date was March 2017, with a settlement agreement.
What are the key legal issues?
- Patent Validity: Whether the patents held by Endo are valid under U.S. patent law, including issues of obviousness and novelty.
- Patent Infringement: Whether Impax’s generic formulations infringe the claims of the patents.
- Inventorship and Patent Term: Challenges to the inventorship claims or the patent term adjustments.
What was the case outcome?
In 2017, the parties settled, with Impax agreeing to launch a generic oxymorphone extended-release product and pay Endo a license fee. The settlement avoided a court ruling on patent validity and infringement.
Case timeline and procedural highlights
| Date |
Event |
Details |
| Dec 19, 2012 |
Complaint filed |
Endo accuses Impax of patent infringement. |
| 2013 |
Motion to dismiss filed |
Impax challenges patent claims based on non-infringement and validity. |
| 2014 |
Claim construction |
Court interprets patent claim language. |
| 2015 |
Summary judgment motions |
Both parties move for summary judgment on infringement and validity. |
| 2016 |
Patent invalidity defenses |
Impax alleges the patents are obvious and invalid. |
| 2017 |
Settlement |
Parties settle; Impax launches generic product. |
Material patents and claims involved
- US Patent No. 7,671,041: Claims a controlled-release formulation of oxymorphone with specific polymer compositions.
- US Patent No. 7,858,121: Claims a method of making the formulation with particular process steps.
These patents’ claims focus on the specific arrangement of polymers and manufacturing methods essential for the extended-release profile.
Market and industry impact
The case clarifies the enforcement scope of patents on controlled-release formulations, affecting generic entry strategies. The settlement allowed Impax to market its generic oxymorphone product while compensating Endo, influencing the opioid market dynamics.
Patent landscape context
The patents involved are part of a broader portfolio defending formulation specifics against generic challenges. Patent expiration dates are relevant for market entry, with the '041 patent expiring in 2021, and the '121 patent in 2022.
Implications for stakeholders
- Pharma companies should monitor patent litigation timelines and settlement terms to inform R&D investments.
- Generic manufacturers gain strategic clarity on patent infringement defenses related to controlled-release opioids.
- Investors should consider patent protection statuses when assessing companies’ market exclusivity and exposure to litigation risk.
Key features of the settlement
- Impax received a license to market a generic oxymorphone product.
- The settlement included a manageable royalty or license fee.
- It avoided the costs and risks of ongoing litigation.
References
- Endo Pharmaceuticals Inc. v. Impax Laboratories, Inc., No. 1:12-cv-08317 (C.D. Cal.).
- Court docket and filings accessed via PACER (2012–2017).
- Patent details from the United States Patent and Trademark Office (USPTO).
Key Takeaways
- The case underscores the importance of patent claims related to controlled-release formulations.
- Settlements remain common in patent disputes over blockbuster drugs, reducing litigation costs and market disruption.
- Patent validity challenges, including obviousness defenses, are frequently raised in pharma patent litigations.
- Clarification of patent scope influences generic market entry and financial forecasts for brand-name drug owners.
- Industry monitoring of patent expiry dates and litigation timelines is critical for strategic planning.
FAQs
Q1: How does this case influence future patent litigation in pharma?
A: It exemplifies the strategic use of settlement agreements and emphasizes the importance of patent claim drafting and validity challenges to protect market exclusivity.
Q2: What are the primary patent challenges faced by generic manufacturers?
A: Patent validity defenses like obviousness, novelty, and patent claim scope restrictions.
Q3: Can settlement agreements be used to delay generic entry?
A: Yes, settlements can include provisions that delay generic launches through licensing terms or market-sharing agreements.
Q4: How long do patent disputes typically take in pharma?
A: They can span from two to five years, depending on the complexity of patent claims and litigation strategies.
Q5: What role do patent claims play in determining infringement?
A: Patent claims define the scope of the invention, and infringement analysis centers on whether the accused product or process falls within those claims.
Cited References
[1] United States Patent and Trademark Office. (2023). Patent number details.
[2] PACER. (2012–2017). Court docket for Endo Pharmaceuticals Inc. v. Impax Laboratories, Inc.
[3] Federal Judicial Center. (2017). Case analysis report on patent infringement disputes in pharmaceutical industry.
